pharmaceutical companies news from FierceBiotech
News
ALSO NOTED: GSK releases new Cervarix data; FDA mulls DTC ads; and much more...
> GlaxoSmithKline has released new Cervarix data that demonstrates the vaccine's ability to generate a high and sustained level of antibodies to neutralize the two most prevalent strains of Read more...
Deloitte sees 'fundamental shift' in drug dev. strategies
Deloitte sees a major shakeup going on in clinical research strategies at the large pharma companies. Instead of focusing on the development of a small portfolio of Read more...
Merck turns to Ranbaxy for $100M R&D effort
India's Ranbaxy has flexed its research muscles once again, this time signing a five-year pact with Merck to develop new anti-infectives. Ranbaxy, which received an undisclosed upfront payment, says Read more...
Biotech M&A has yet to reach its peak
In analyzing the PowerShares Dynamic Biotech & Genome ETF, a fund made up of primarily small- and medium-cap biotech stocks, Seeking Alpha notes that Big Pharma's appetite for biotech Read more...
Traditional remedies offer opportunities, challenges
The Financial Times delves into the push to develop new therapeutics from traditional Chinese and Indian remedies. There have been successes, including the anti-malarial artemether, which was Read more...
Biotech's next big opportunity: Follow-ons?
Follow-on biologics are often cited as major long-term threat to the biotech industry, which so far has not had to face a future where generic therapies are allowed to slice and dice the market for Read more...
ALSO NOTED: Arqule hires new CEO; Kosan launches mid-stage study; and much more...
> Is the U.S. drug industry bargain-basement land right now? Analysts say that the low, low dollar means low, low prices for pharma companies. Rivals in Asia and the Eurozone could snap up drug Read more...
ALSO NOTED: Meda buys late-stage drugs;Debiopharm licenses peptide;and much more...
> How might drugmakers navigate the rocky waters of generic competition, cautious regulators, safety scandals, globalization, and so on? Seek help with the itinerary from an expert, perhaps. At Read more...
Avanir gets $40 to wrap new Phase III for Zenvia
A group of venture firms led by ProQuest Investors is providing Avanir Pharmaceuticals with $40 million to fund a confirmatory late-stage trial of Read more...
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight